Boston Scientific Co. (NYSE:BSX) Shares Bought by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. grew its position in Boston Scientific Co. (NYSE:BSX) by 91.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,098 shares of the medical equipment provider’s stock after acquiring an additional 35,336 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Boston Scientific were worth $6,210,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Triad Wealth Partners LLC bought a new stake in Boston Scientific during the second quarter valued at $26,000. Values First Advisors Inc. bought a new stake in shares of Boston Scientific during the 3rd quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. acquired a new stake in Boston Scientific during the third quarter worth about $30,000. Capital Performance Advisors LLP bought a new position in Boston Scientific in the third quarter worth about $30,000. Finally, Andra AP fonden acquired a new position in Boston Scientific in the second quarter valued at approximately $29,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Up 0.6 %

Shares of BSX stock opened at $90.75 on Friday. The stock has a 50-day simple moving average of $86.57 and a 200 day simple moving average of $80.58. The stock has a market capitalization of $133.75 billion, a P/E ratio of 75.00, a P/E/G ratio of 2.63 and a beta of 0.79. Boston Scientific Co. has a fifty-two week low of $53.93 and a fifty-two week high of $91.93. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific’s revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.50 EPS. On average, sell-side analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares in the company, valued at approximately $3,061,135.60. This represents a 15.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of Boston Scientific stock in a transaction on Monday, October 7th. The stock was sold at an average price of $85.00, for a total value of $11,264,795.00. Following the completion of the transaction, the executive vice president now owns 160,467 shares in the company, valued at $13,639,695. The trade was a 45.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 328,157 shares of company stock worth $27,894,270. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. TD Cowen increased their price target on Boston Scientific from $86.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Morgan Stanley increased their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, October 24th. BTIG Research boosted their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a report on Monday, October 14th. Citigroup increased their price objective on shares of Boston Scientific from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.